2023 HCPCS Code Q2053
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
| Short Description | Brexucabtagene car pos t |
HCPCS Coverage Code 
|
C = Carrier judgment |
|
HCPCS Action Code
|
N = No maintenance for this code |
|
HCPCS Action Effective Date
|
April 01, 2021 |
|
HCPCS Code Added Date
|
April 01, 2021 |
|
HCPCS Pricing Indicator Code
|
51 = Drugs |
|
HCPCS Multiple Pricing Indicator Code
|
A = Not applicable as HCPCS priced under one methodology |
|
HCPCS Type Of Service Code
|
1 = Medical care
P = Lump sum purchase of DME, prosthetics, orthotics |
|
HCPCS Anesthesia Base Unit Quantity
|
0 |